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CASE REPoRT
CASE REPORT
A 68-year-old white non-smoker woman was admitted to 
our department for the symptomless radiological evidence 
of two bilateral pulmonary lesions detected during the rou-
tine follow-up for a breast cancer diagnosed and cured in 
2001. A computed tomography (CT)-scan revealed a round 
irregularly shaped lesion in the left upper lobe (LUL), 
1.8 cm in the major axis (Figure 1A) and a synchronous 
pseudonodular contralateral lesion in the right upper lobe 
(RUL), measuring 1.4 cm (Figure 1E. The positron emis-
sion tomography (PET)-CT scan (18F-FDG/PET-CT) char-
acterized the LUL lesion with a SUV of 7.3 (Figure 1B) and 
the RUL one of 1.7 (Figure 1D). According to the oncologi-
cal history, a resection of the left nodule was chosen as first 
step and a wedge resection was performed. Intraoperative 
histology was strongly suggestive for lung adenocarci-
noma, so the patient underwent a left apico-dorsal segmen-
tectomy plus systematic mediastinal lymphadenectomy. 
Final pathology confirmed a G3 adenocarcinoma with a 
G2 component, pT1aN0 (AJCC 2010) (Figure 2A–D). one 
month later, cytology obtained by a fine-needle aspiration 
biopsy of the RUL nodule was suggestive of adenocarci-
noma. A right upper segmentectomy was performed and 
final pathology confirmed a G2 adenocarcinoma of very 
probable lung origin (Figure 2E–F). To definitely confirm 
the primary nature of the two lung nodules with respect to 
the previous breast cancer and to further differentiate the 
two lesions, we performed a epidermal growth factor recep-
tor (EGFR) mutational analysis to establish clonality. We 
identified an EGFR exon 19 microdeletion (∆E746–A750) 
in the LUL adenocarcinoma (Figure 3A) and an exon 21 
mutation (L858R) in the RUL one (Figure 3B). Based on 
this finding that confirmed different DNA profiles, a cer-
tain diagnosis of synchronous primary non–small cell lung 
cancer (NSCLC) was achieved.
DISCUSSION
The Martini and Melamed criteria1 are still widely used for 
the management of multiple primary lung cancers (MPLCs), 
although a comprehensive histologic assessment allows a more 
accurate diagnosis.2 Clinically, the distinction of clonality in 
patients with synchronous primary cancers is relevant thera-
peutically and prognostically. Nowadays, detection of EGFR 
alterations can improve the clonality assessment because of 
the frequently mutated exons on EGFR genes (exons 18–22) 
in NSCLC.3
In the case we report, the assessment of the primary or second-
ary nature of the two nodules was pivotal for the therapeutic 
strategy: in brief, ruling out the metastatic nature of the lung 
lesions (with respect to the previously cured breast cancer or 
to lung neoplasm) allowed us to plan for a radical surgery with 
curative intent. According to the different prognosis related 
to metastatic and early-stage NSCLCs, the different EGFR 
mutational profiles as detected in both lesions allowed a pre-
cise diagnosis and staging. A radical surgery, considered to be 
the treatment of choice for synchronous MPLCs,4 is further 
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FIGURE 1. CT scan revealed (A) a round irregularly shaped 
lesion in the left upper lobe (LUL), 1.8 cm in the major axis; 
(C) synchronous pseudonodular contralateral lesion in the 
right upper lobe (RUL), measuring 1.4 cm. The PET-CT scan 
characterized (B) the LUL lesion with a SUV of 7.3 (D)and the 
RUL one of 1.7.
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justified by the evidence that onco-developmentally indepen-
dent (lung) adenocarcinomas have a better prognosis if com-
pared to tumors with the same EGFR profile.3
Interestingly, the case we report supports the recently reported 
findings that there is a significant correlation of the 18F-FDG/
PET-CT SUV (< 9.2) and NSCLC-patients harboring EGFR 
mutations.5 Further investigation is needed to understand the 
predictive potential of this correlation.
In conclusion, we advocate that the EGFR mutational 
analysis should be routinely performed in NSCLCs, either for 
planning targeted therapy, either in case of MPLCs, to help 
FIGURE 2. (A) Moderately differentiated component of the left upper lobe (LUL) adenocarcinoma composed of papillary struc-
tures with a central fibrovascular core lined by columnar cells with moderate cyto-nuclear atypia; neoplastic cells exhibit a diffuse 
nuclear immunoreactivity for TTF-a (B), (A) Haematoxylin and eosin (B) haematoxylin counterstaining; original magnification 
×200, (C) Poorly differentiated component of the LUL adenocarcinoma with a solid grow pattern, composed of sheets of polygo-
nal cells sometimes markedly anaplastic with a high mitotic count and a weak and focal nuclear positivity for TTF-1 (D), 
(C) Haematoxylin and eosin (D) haematoxylin counterstaining, original magnification ×200, (E) The right upper lobe neoplasm 
is a moderately differentiated adenocarcinoma showing the same morphological and immunohystochemical features of the first, 
with papillary structures lined by columnar cells diffusely stained for TTF-1 in a nuclear pattern (F), (E) Haematoxylin and eosin, 
(F) haematoxylin counterstaining, original magnification × 200.
FIGURE 3. Partial nucleotide 
sequence of (A) exon 19 and (B) 
exon 21 of the EGFR gene. The 
exon 19 shows a heterozygous 
deletion of five amino-acids from 
746 to 750 position (∆E746–A750) 
as shown by the arrow indicating 
the starting point of frame shift. 
The exon 21 shows a heterozy-
gous mutation at code 858 (CTG 
> CGG) with a substitution of 
arginine for leucine at position 858 
(L858R); the arrow indicates the 
point mutation (T > G).
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discriminating the primary or secondary nature of the syn-
chronous lesions.
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